Treatment.com AI and SPRYT Partner to Revolutionize Patient Access in Healthcare

Revolutionary AI collaboration aims to streamline healthcare, reduce administrative costs, and improve patient access globally.

Editorial Team (ET)May 8, 2025

In a new groundbreaking collaboration, Treatment.com AI and SPRYT Limited have joined forces to address the pressing challenges of patient access and administrative inefficiencies in healthcare. With a combined focus on leveraging artificial intelligence (AI) technology, the collaboration aims to streamline patient onboarding, reduce missed appointments, and alleviate administrative burdens, creating a more efficient and patient-friendly healthcare system.

Revolutionizing Healthcare with AI

Artificial intelligence is revolutionizing how healthcare systems operate, and this collaboration between Treatment.com AI and SPRYT is a prime example of how AI can address some of the most significant challenges facing the sector today. By merging their respective technological strengths, both companies aim to improve healthcare delivery in key areas, particularly patient access, scheduling, and administrative efficiency.

The Partnership Between Treatment.com AI and SPRYT

The collaboration brings together Treatment.com AI's proprietary Global Library of Medicine (GLM) and SPRYT's AI receptionist, Asa, to create a powerful AI-driven solution for healthcare providers. The GLM offers healthcare professionals access to a vast repository of medical knowledge, assisting in the diagnosis and triage of patients. Meanwhile, Asa serves as a Medical Office Assistant (MOA) that automates scheduling, billing, and appointment management, all through standard messaging platforms like WhatsApp and SMS.

This combination of capabilities allows the partnership to tackle some of the most costly and time-consuming aspects of healthcare, notably the $1 trillion spent annually in the U.S. on administrative tasks, according to McKinsey.

Solving the Administrative Burden in Healthcare

Administrative overhead is a significant drain on healthcare resources. In the U.S. alone, nearly 25% of healthcare spending—over $1 trillion annually—is attributed to tasks like scheduling, billing, and patient data management. Furthermore, missed appointments add to the burden, with an estimated $150 billion lost annually due to no-shows.

Through this collaboration, Asa, the AI receptionist, steps in to reduce these costs by automating administrative functions. Patients can use Asa to book, change, and pay for appointments directly through their mobile devices, eliminating the need for manual intervention from office staff. Asa also predicts potential no-shows and adjusts communication strategies to encourage attendance, reducing the impact of missed appointments on healthcare providers.

SPRYT’s Asa: A Game-Changer in Patient Interaction

Asa, SPRYT’s AI-powered Medical Office Assistant, represents a significant advancement in patient interaction. Unlike other systems that require users to download specific apps, Asa functions entirely through popular messaging platforms like WhatsApp, SMS, and iMessage. This ensures accessibility and ease of use for patients of all demographics, making it a versatile tool for healthcare systems around the world.

By leveraging behavioral science, Asa can predict patient behavior, such as the likelihood of missing an appointment, and tailor its communication to encourage timely attendance. This feature is particularly valuable for improving healthcare access in underserved populations, as it adjusts messaging according to different patient needs.

Treatment.com AI’s Global Library of Medicine (GLM): Redefining Diagnostics

Treatment.com AI’s Global Library of Medicine (GLM) offers a robust platform that assists healthcare professionals in diagnosing patients and recommending necessary tests. The GLM analyzes patient data, including symptoms and medical history, to suggest possible diagnoses and identify critical exams or lab tests. This streamlines the patient triage process, allowing healthcare providers to focus on delivering timely and effective care.

By integrating with SPRYT’s Asa, the GLM further enhances the patient onboarding process. Asa can collect patient information, which is then analyzed by the GLM to provide healthcare providers with a detailed medical history and diagnostic recommendations, all before the patient arrives for their appointment.

Enhancing Patient Access and Reducing Costs

The collaboration between Treatment.com AI and SPRYT is set to improve patient access to healthcare services in several ways. By automating the scheduling and administrative process, Asa ensures that patients can easily book appointments, while the GLM provides healthcare providers with the information they need to deliver care efficiently. This partnership is poised to create cost savings for healthcare providers and payers, while simultaneously improving patient outcomes.

Missed appointments, which cost U.S. healthcare providers billions of dollars annually, are expected to decrease as Asa’s AI-driven messaging system predicts and mitigates no-shows. Additionally, the automation of administrative tasks like billing and appointment management reduces the need for manual intervention, allowing healthcare staff to focus on patient care rather than paperwork.

Global Impact: Expanding Healthcare Solutions Worldwide

While the partnership between Treatment.com AI and SPRYT is already making strides in the UK, North America, and the Middle East, the potential for global impact is significant. Asa’s integration with messaging platforms like WhatsApp makes it a versatile solution that can be implemented in various healthcare systems worldwide, particularly in regions where administrative inefficiencies and access challenges are prominent.

The combination of Asa’s AI-driven appointment management and the GLM’s diagnostic capabilities positions this collaboration as a leader in healthcare innovation. Both companies are exploring additional opportunities for expansion and commercialization, with the aim of making their AI-driven solutions available to healthcare providers and patients across the globe.

Statements from Key Executives

Dr. Essam Hamza, CEO of Treatment.com AI, highlighted the potential of the partnership: “This collaboration with SPRYT allows us to leverage our AI-driven Global Library of Medicine to improve access and outcomes for patients. By reducing missed appointments and enhancing triage processes, we are addressing some of the most pressing challenges in healthcare today.”

Daragh Donohue, Founder and CEO of SPRYT, echoed these sentiments, stating: “We are excited to work with Treatment.com to combine Asa, our AI receptionist, with their GLM. Together, we can significantly improve the patient experience, reduce administrative burdens, and create a more efficient healthcare ecosystem.”

Conclusion

The collaboration between Treatment.com AI and SPRYT is set to transform the healthcare landscape by reducing administrative inefficiencies, improving patient access, and enhancing healthcare outcomes. By combining AI-powered solutions like Asa and the Global Library of Medicine, the partnership is creating a more streamlined and patient-centric healthcare system that addresses some of the most critical challenges facing the industry today.

Disclaimer

This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.